Predictive value of dual-time 18 F-FDG PET/CT to distinguish primary lung and metastatic adenocarcinoma in solitary pulmonary nodule

Abstract

Aims and background:

Distinction between primary lung adenocarcinoma and metastatic adenocarcinoma from extrapulmonary origin in solitary pulmonary nodule (SPN) is crucial for cancer treatment. We investigated the predictive role of dual-time-point ¹⁸F-FDG PET/CT to distinguish primary and metastatic lung adenocarcinoma in SPN.

Methods:

A total of 96 consecutive patients with newly diagnosed SPN and biopsy-proven adenocarcinoma were enrolled in this study, retrospectively (54 male; 42 female; age 59.68 ± 8.2 years). They all underwent dual-time-point ¹⁸F-FDG PET/CT at 60 minutes (early) for whole body and 120 minutes (delayed) for chest region after FDG injection. Maximum standardized uptake values (early SUVmax and delayed SUVmax) and retention index (RI) were acquired for analysis. Final pathology results were confirmed by surgical specimens.

Results:

Metastatic adenocarcinoma showed significantly higher early SUVmax, delayed SUVmax, and RI compared to primary lung adenocarcinoma. Delayed SUVmax and RI presented superior diagnostic performance for prediction of metastatic adenocarcinoma than early ¹⁸F-FDG PET/CT. Among metastatic adenocarcinoma, metastasis from colorectal origin showed significantly higher RI than from other origins. In addition, RI significantly predicted metastatic adenocarcinoma from colorectal cancer than early or delayed SUVmax.

Conclusions:

Dual-timepoint ¹⁸F-FDG PET/CT can be useful to distinguish primary and metastatic lung adenocarcinoma in SPN. Furthermore, it may also be useful to predict metastatic adenocarcinoma from colorectal origin.

Keywords

Solitary pulmonary nodule primary lung cancer pulmonary metastasis

Get full access to this article

View all access options for this article.

References

Ost

Fein

Feinsilver

SH.

Clinical practice: The solitary pulmonary nodule. N Engl J Med 2003; 348: 2535–2542.

Wahidi

Govert

Goudar

et al . American College of Chest Physicians: Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer? ACCP evidence-based clinical practice guidelines (2^nd edition). Chest 2007; 132: 94S–107S.

Quint

Park

Iannettoni

MD.

Solitary pulmonary nodules in patients with extrapulmonary neoplasm. Radiology 2000; 217: 257–261.

Truong

Rossi

et al . Update in the evaluation of the solitary pulmonary nodule. Radiographics 2014; 34: 1658–1679.

Rena

Papalia

Ruffini

et al . The role of surgery in the management of solitary pulmonary nodule in breast cancer patients. Eur J Surg Oncol 2007; 33: 546–550.

Okasaka

Usami

Mitsudomi

et al . Stepwise examination for differential diagnosis of primary lung cancer and breast cancer relapse presenting as a solitary pulmonary nodule in patients after mastectomy. J Surg Oncol 2008; 98: 510–514.

Ung

Maziak

Vanderveen

et al . Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care: ¹⁸Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systemic review. J Natl Cancer Inst 2007; 99: 1753–1767.

Madsen

Holdgaard

Christensen

JB, et al.

Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2084–2097.

Alkhawaldeh

Bural

Kumar

et al . Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2008; 35: 246–252.

10.

Hamberg

Hunter

Alpert

et al . The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35: 1308–1312.

11.

Zhuang

Pourdehnad

Lambright

et al . Dual time point ¹⁸F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42: 1412–1417.

12.

Ponzo

Zhuang

Liu

Can the difference of the level of glucose-6 phosphatase explain the mechanism of FDG-PET dual time point imaging?

Eur J Nucl Med 2001; 28: 1063.

13.

Schrevens

Lorent

Dooms

C, et al.

The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 2004; 9: 633–643.

14.

Edge

Compton

CC.

The American Committee on Cancer: the 7^th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471–1474.

15.

Ginsberg

Rubinstein

LV.

Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615–622.

16.

Kim

Cho

Lee

et al . Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times? World J Gastroenterol 2014; 20: 6133–6145.

17.

Walker

Alattar

Gautam

Repeat needle biopsies combined with clinical observation are safe and accurate in the management of a solitary pulmonary nodule. Cancer 2005; 103: 599–607.

18.

Yang

Sun

et al . Diagnostic accuracy of CT-guided transthoracic needle biopsy for solitary pulmonary nodule. PLoS One 2015; 10: e0131373.

19.

Shimizu

Okita

Saisho

et al . Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer. Ann Nucl Med 2015; 29: 854–860.

20.

Satoh

Nambu

Onishi

et al . Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Eur J Radiol 2012; 81: 3530–3534.

21.

Lee

Park

et al . Relationship between dual-time point FDG PET and immunohistochemical parameters in preoperative colorectal cancer: preliminary study. Nucl Med Mol Imaging 2012; 46: 48–56.

22.

Petitjean

Mathe

Kato

et al . Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622–629.